Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mark I. Attard"'
Autor:
Thomas M. Attard, Seth Septer, Caitlin E. Lawson, Mark I. Attard, Sonny T. M. Lee, Shahid Umar
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-17 (2022)
Abstract Background Individuals with familial adenomatous polyposis (FAP) harbor numerous polyps with inevitable early progression to colon cancer. Complex microbiotic-tumor microenvironment perturbations suggest a dysbiotic relationship between poly
Externí odkaz:
https://doaj.org/article/05f3b5ccd64a48bf927fb5a250e1897a
Autor:
John Wharton, Christopher J. Rhodes, Martin R. Wilkins, Lars Harbaum, Pavandeep Ghataorhe, Mark I Attard
Publikováno v:
Journal of Internal Medicine. 282:129-141
Pulmonary arterial hypertension (PAH), at one time a largely overlooked disease, is now the subject of intense study in many academic and biotech groups. The availability of new treatments has increased awareness of the condition. This in turn has dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7998221c9e1faea54ced164565e941a
https://doi.org/10.1111/joim.12623
https://doi.org/10.1111/joim.12623
Autor:
Carlo, Biffi, Antonio, de Marvao, Mark I, Attard, Timothy J W, Dawes, Nicola, Whiffin, Wenjia, Bai, Wenzhe, Shi, Catherine, Francis, Hannah, Meyer, Rachel, Buchan, Stuart A, Cook, Daniel, Rueckert, Declan P, O'Regan
Publikováno v:
Bioinformatics
Motivation Left ventricular (LV) hypertrophy is a strong predictor of cardiovascular outcomes, but its genetic regulation remains largely unexplained. Conventional phenotyping relies on manual calculation of LV mass and wall thickness, but advanced c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6fc0c3fb70482829598389176c24a4e2
https://pubmed.ncbi.nlm.nih.gov/28968671
https://pubmed.ncbi.nlm.nih.gov/28968671
Autor:
Pavandeep Ghataorhe, Martin R. Wilkins, Christopher J. Rhodes, John Wharton, Mark P. Lythgoe, Mark I Attard
The past three decades have witnessed a welcome expansion of the therapeutic armamentarium for the management of pulmonary arterial hypertension (PAH). However, against this backdrop, there have been some notable disappointments in drug development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dffae7ec9e35a162b8edce055849100
http://hdl.handle.net/10044/1/32478
http://hdl.handle.net/10044/1/32478
Publikováno v:
Gastroenterology. 120:A211-A212
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b1ef849db4e8709ea95dd2512de78a6
https://doi.org/10.1016/s0016-5085(08)81051-7
https://doi.org/10.1016/s0016-5085(08)81051-7